Stanislaw Pikul

ORCID: 0009-0009-0199-7045
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune cells in cancer
  • Cancer Research and Treatments
  • Adenosine and Purinergic Signaling
  • Receptor Mechanisms and Signaling
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Nanoplatforms for cancer theranostics
  • Monoclonal and Polyclonal Antibodies Research
  • Amino Acid Enzymes and Metabolism
  • Click Chemistry and Applications
  • Cell Adhesion Molecules Research
  • S100 Proteins and Annexins
  • Inflammatory mediators and NSAID effects
  • Cancer-related gene regulation

Pharmacologic inhibition of the controlling immunity pathway enzymes arginases 1 and 2 (ARG1 ARG2) is a promising strategy for cancer immunotherapy. Here, we report discovery development OATD-02, an orally bioavailable, potent inhibitor. The unique pharmacologic properties OATD-02 are evidenced by targeting intracellular ARG1 ARG2, as well long drug-target residence time, moderate to high volume distribution, low clearance, which may jointly provide weapon against arginase-related tumor...

10.1158/1535-7163.mct-22-0721 article EN Molecular Cancer Therapeutics 2023-03-17

<div>Abstract<p>Pharmacological inhibition of the controlling immunity pathway enzymes arginases 1 and 2 (ARG1 ARG2) is a promising strategy for cancer immunotherapy. Here, we report discovery development OATD-02, an orally bioavailable, potent inhibitor. The unique pharmacological properties OATD-02 are evidenced by targeting intracellular ARG1 ARG2, as well long drug-target residence time, moderate to high volume distribution, low clearance which may jointly provide weapon...

10.1158/1535-7163.c.6727163.v2 preprint EN 2024-09-16
Coming Soon ...